Publications

Comparison of glycosylated fibronectin versus soluble fms-like tyrosine kinase/placental growth factor ratio testing for the assessment of pre-eclampsia: protocol for a multicentre diagnostic test accuracy study
Elbarbary N, Wang C, Ganapathy R, et al. BMJ Open 2025;15:e093586.

Clinical utility of a glycosylated fibronectin test (LumellaTM) for
assessment of impending preeclampsia
Gian Carlo Di Renzo , Maurizio Arduini , Jose Luis Bartha , Alizee Froeliger ,
Jan Stener Jorgensen , Marian Kacerovsky , Pawel Stanirowski, Miroslaw Wielgos , Lina Gao
& Michael G. Gravett (2025), The Journal of Maternal-Fetal & Neonatal Medicine,
38:1, 2474674

Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complications
Anna C.M. Kluivers, Rugina I. Neuman, Bhanu Kalra, Ajay Kumar, Willy Visser, A.H. Jan Danser, Langeza Saleh. Pregnancy Hypertension, Volume 39, March 2025, 101177

Point-of-Care Tests for Preeclampsia: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies
Elbarbary, N., Pritsini, F., Kazi, A., Wang, C., Thilaganathan, B. and Bhide, A. (2024) BJOG 0:1–12

Intermanufacturer assessment of diagnostic performance of angiogenic ratio vs glycosylated fibronectin in women with suspected pre-eclampsia
I. Y. M. Wah, D. S. Sahota, N. K. L. Wong, N. M. W. Lee, C. J. Liu, C. S. L. Lau, H. H. Y. Leung, L. C. Poon. Ultrasound Obstet Gynecol 2024; 64: 620–625

Diagnostic accuracy of serum glycosylated fibronectin in prediction of preeclampsia: A nested case–control study
Sachan R, Sachan PL, Ghayyur N, Patel ML, Ali W. Ann Afr Med 2024;23:169‑75

Anti-Citrullinated Albumin Antibodies as Biomarker for the Diagnosis of Rheumatoid Arthritis.
Paturi VR, Uppuluri RR, Gao L, Roberts CT, Nagalla SR (2024) Rheumatology (Sunnyvale). 14: 362.

Diagnostic and prognostic utility of anti-modified albumin autoantibodies in rheumatoid arthritis
Wang et al. Archives of Rheumatology & Arthritis Research (2022)

Rapid Point-of-Care Test for Determination of C-Peptide Levels
Rao et al. Journal of Diabetes Science and Technology (2021)

Glycosylated fibronectin point‐of‐care test for diagnosis of pre‐eclampsia in a low‐resource setting: a prospective Southeast Asian population study
Nagalla SR, Janaki V, Vijayalakshmi AR, Chayadevi K, Pratibha D, Rao PV, Sage KM, Nair-Schaef D, Bean E, Roberts CT Jr, Gravett MG. BJOG 2020

Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study.
Huhn, E.A., Hoffmann, I., Martinez De Tejada, B. et al. BMC Pregnancy Childbirth 20, 128 (2020).

Salivary Protein Glycosylation as a Noninvasive Biomarker for Assessment of Glycemia.
Rao PV, Laurie A, Bean ES, Roberts, CTJr, Nagalla SR. J Diabetes Sci Technol 2015 9:97-104

Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia.
Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CTJr, Nagalla SR, Gravett MG. Am J Obstetr Gynecol 2015 212:82.e1-9

Glycosylated Fibronectin as a First-Trimester Biomarker for Prediction of Gestational Diabetes.
Rasanen JP, Snyder CK, Rao PV, Mihalache R, Heinonen S, Gravett MG, Roberts CTJr, Nagalla SR. Obstetr Gynecol 2013 122:586-94

Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia.
Rasanen J, Girsen A, Lu X, Lapidus JA, Standley M, Reddy A, Dasari S, Thomas A, Jacob T, Pouta A, Surcel HM, Tolosa JE, Gravett MG, Nagalla SR. J Proteome Res 2010 9:4274-81

Proteomic identification of salivary biomarkers of type-2 diabetes.
Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT, Nagalla SR. J Proteome Res 2009 8:239-45

Proteomic identification of urinary biomarkers of diabetic nephropathy.
Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, Dakshinamurthy KV, Roberts CTJr, Nagalla SR. Diabetes Care 2007 30:629-37